Clinical Trials Logo
  1. Home
  2. Recurrent Endometrial Cancer
  3. NCT02755844

Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients — ENDOLA  

Recurrent Endometrial Cancer Clinical Trial

Official title:
A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients

Clinical Trial Summary

Endometrial cancer ranks 11th in terms of incidence (7275 / year) and mortality (2025 deaths/ year). The 5-year overall survivals of patients at diagnosis with locally advanced and metastatic carcinomas are about 50% and 15% respectively. Beyond first line treatment with platinum-based chemotherapy, there is lack of effective drug in this disease, which explains the poor prognosis of patients. The prognosis of metastatic endometrial cancer patients is poor, and few drugs have been shown to be effective beyond first chemotherapy line. Endometrial carcinomas are characterized by frequent alterations of PI3K-AKT-mTor; IGF1R and of DNA repair pathways. Phosphatase and tensin homologue (PTEN)-phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTor) and DNA repair pathways interact, and inhibition of PI3K-AKT-mTor signaling pathway may alter DNA damage repair. Metronomic cyclophosphamide regimen may increase the anti-proliferative effects of olaparib because it is an alkylating agent, and it exerts anti-angiogenic effects, with a favorable toxicity profile. Metformin may increase the anti-proliferative effects of olaparib because it downregulates IGF1R and PI3K-AKT-mTor pathways, with no additive toxicity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02755844
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 23, 2016
Completion date June 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05419817 - Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Phase 2
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Active, not recruiting NCT02899793 - Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Phase 2
Completed NCT02549989 - Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Phase 2
Completed NCT02788708 - Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Phase 1
Recruiting NCT03564340 - Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Phase 1/Phase 2
Enrolling by invitation NCT01454479 - A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Phase 1
Terminated NCT03277482 - Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Phase 1
Terminated NCT04906382 - Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Early Phase 1
Withdrawn NCT02117817 - Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer Phase 1
Withdrawn NCT04197219 - Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Phase 2
Active, not recruiting NCT05263492 - Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer Phase 2